UBRELVY—

the ANYTIME, ANYWHERE migraine medicineTM for quick pain relief2-5†

UBRELVY is not indicated for the preventive treatment of migraine.

References

1. Gallagher R, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache. 2003;43(1):36-43. 2. Data on file. Allergan. 3. UBRELVY [package insert]. Madison, NJ: Allergan USA, Inc.; 2020. 4. Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain from the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887-1898. 5. Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230-2241. 6. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies—successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338-350.